AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05434312
Drug: TGRX-678
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
Trial: NCT05675605
Drug: TY-1091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
Trial: NCT04656275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05648656
Drug: TXA Nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
Trial: NCT06413433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken once daily
Trial: NCT05561010
Drug: Intra-articular injection of placebo in the knee joint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 participants will be allocated to the placebo arm.
Trial: NCT06061718
Drug: iDose TR
RxNorm normalized name: iDose TR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anchored intracameral implant containing travoprost
Trial: NCT06432647
Drug: ATH-1105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
Trial: NCT06432647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
Trial: NCT05509946
Drug: Single dose of celecoxib 400 mg and pregabalin 150 mg
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of celecoxib 400 mg and pregabalin 150 mg
Trial: NCT05509946
Drug: Repeated dose of celecoxib 200 mg and pregabalin 75 mg
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
Trial: NCT05509946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06800157
Drug: Drug: LW402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered BID
Trial: NCT06800157
Drug: Other: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match LW402 administered BID
Trial: NCT06800196
Drug: KNT-0916
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • KNT-0916 is an oral inhibitor of FGFR2.
Trial: NCT06314620
Drug: Heparin saline lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
Trial: NCT04722653
Drug: NNC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose administered subcutaneously (s.c. - under the skin)
Trial: NCT04722653
Drug: Placebo (NNC0194-0499 )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose administered subcutaneously (s.c. - under the skin).
Trial: NCT05497700
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
Trial: NCT05573373
Drug: Targeted Therapy Agent
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage and protocol of the drug were carried out according to the description.
Trial: NCT05187403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye-drops
Trial: NCT04826003
Drug: RO7122290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
Trial: NCT05051150
Drug: Epinephrin 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Trial: NCT04711252
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage formulation: AZD9833 tablets will be administered orally
Trial: NCT05085197
Drug: STSA-1005 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05085197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05256017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of placebo (3 tablets of 320 mg) on Day 1
Trial: NCT06309472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
Trial: NCT06457464
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
Trial: NCT06339021
Drug: DAPT de-escalation
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel 30 days after DES implantation
Trial: NCT06339021
Drug: default DAPT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticagrelor 30 days after DES implantation
Trial: NCT06282588
Drug: Zoladex 3.6Mg Implant
RxNorm normalized name: Zoladex 3.6mg Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg, subcutaneous use
Trial: NCT06282588
Drug: Decapeptyl sustained release 22.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 mg, intramusculair injection
Trial: NCT06282588
Drug: Decapeptyl sustained release 11.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg, intramusculair injection
Trial: NCT06282588
Drug: Depo-Eligard 45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg, subcutaneous use
Trial: NCT06282588
Drug: Depo-Eligard 22.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 mg, subcutaneous use
Trial: NCT06282588
Drug: Depo-Eligard 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg, subcutaneous use
Trial: NCT05852587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
Trial: NCT04609111
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month prasugrel monotherapy followed by clopidogrel monotherapy
Trial: NCT04744571
Drug: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
Trial: NCT05968937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppository composed of Supposibase F daily per vagina
Trial: NCT05867251
Drug: AVZO-021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
Trial: NCT05539833
Drug: KSH01 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T cell injection
Trial: NCT05125016
Drug: REGN4336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
Trial: NCT05445934
Drug: FB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
Trial: NCT05003895
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
Trial: NCT05445934
Drug: FB2001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
Trial: NCT06584812
Drug: Tiprogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Trial: NCT06584812
Drug: Tiprogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Trial: NCT04195633
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06710600
Drug: Single oral dose of selected medicines, respectively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg
Trial: NCT06710600
Drug: Single oral dose of selected medicines, respectively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg
Trial: NCT06043323
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06043323
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05211401
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
Trial: NCT06707051
Drug: Calcium dobesilate (Doxium)
RxNorm normalized name: calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
Trial: NCT06709716
Drug: Local Anesthetic Solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of 0.25% bupivacaine at each incision site
Trial: NCT06709716
Drug: Local Anesthetic Solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of saline at each incision site.
Trial: NCT06758752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice daily for 3 weeks after enrolment
Trial: NCT06781970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Trial: NCT02069288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo per os
Trial: NCT05935527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
Trial: NCT05113901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
Trial: NCT06798519
Drug: HNC364 Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.
Trial: NCT05285332
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy or chemotherapy or targeted therapy
Trial: NCT05131997
Drug: AD-221C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8 weeks
Trial: NCT05602311
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
Trial: NCT06550024
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection in the knee
Trial: NCT06306612
Drug: Systemic Chemohormonal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
Trial: NCT06532006
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Trial: NCT05476042
Drug: Prescription of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT04632992
Drug: Investigator's Choice of Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
Trial: NCT06333041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
Trial: NCT04234022
Drug: Lanalidomide with Zn-DDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Trial: NCT04670068
Drug: CAR.B7-H3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
Trial: NCT04670068
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 IV for 3 consecutive days
Trial: NCT05492019
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 50 mg capsule twice daily for 8 weeks.
Trial: NCT05492019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo identical to Doxycycline
Trial: NCT04652700
Drug: ISL
RxNorm normalized name: Dartisla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISL 60 mg tablet, QM, orally for up to 24 months
Trial: NCT04652700
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
Trial: NCT04652700
Drug: FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
Trial: NCT04652700
Drug: Placebo to ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ISL 0 mg tablets QM, orally for up to 24 months.
Trial: NCT04652700
Drug: Placebo to FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
Trial: NCT04652700
Drug: Placebo to FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
Trial: NCT05289063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Trial: NCT05955066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily
Trial: NCT06098833
Drug: Ora-Blend
RxNorm normalized name: Ora-Blend Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Trial: NCT06105060
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
Trial: NCT05052996
Drug: ISL
RxNorm normalized name: Dartisla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally without regard to food
Trial: NCT05052996
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT05258071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use
Trial: NCT05721755
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05745064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Trial: NCT05050747
Drug: HCG is introduced at day of trigger intra-uterine
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hcg is introduced
Trial: NCT05929755
Drug: Gel-Flow NT
RxNorm normalized name: Gel-Flow NT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemostatic agent
Trial: NCT04944706
Drug: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 3 times a day after meals,24 weeks
Trial: NCT05778188
Drug: RLS-0071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
Trial: NCT05778188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Trial: NCT06227221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
Trial: NCT06019559
Drug: K-757 120 mg BID and K-833 100 mg BID
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally.
Trial: NCT06019559
Drug: K-757 120 mg BID and matching placebo to K-833
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally.
Trial: NCT06019559
Drug: Matching placebo to K-757 and matching placebo to K-833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally.
Trial: NCT04697810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules q12hours x 36 weeks
Trial: NCT05861687
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered twice a day per-oral with the dose of 7.5 mg/kg
Trial: NCT06501196
Drug: BH-30236
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.
Trial: NCT06519968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as DPI.